Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Portal-vein thrombosis (PVT) develops in 10–25% of cirrhotic patients and may aggravate portal hypertension. There are few data regarding the effects of anticoagulation on nonmalignant PVT in liver cirrhosis. The aim of this study was to elucidate the safety, efficacy, and predictors of response to anticoagulation therapy in cirrhotic patients. Methods: Patients with liver cirrhosis and nonmalignant PVT were identified by a hospital electronic medical record system (called BESTCARE). Patients with malignant PVT, Budd-Chiari syndrome, underlying primary hematologic disorders, or preexisting extrahepatic thrombosis were excluded from the analysis. Patients were divided into two groups (treatment and nontreatment), and propensity score matching analysis was performed to identify control patients. The sizes of the thrombus and spleen were evaluated using multidetector computed tomography . Results: Twenty-eight patients were enrolled in this study between 2003 and 2014: 14 patients who received warfarin for nonmalignant PVT and 14 patients who received no anticoagulation. After 112 days of treatment, 11 patients exhibited significantly higher response rates (complete in 6 and partial in 5) compared to the control patients, with decreases in thrombus size of >30%. Compared to nonresponders, the 11 responders were older, and had a thinner spleen and fewer episodes of previous endoscopic variceal ligations, whereas pretreatment liver function and changes in prothrombin time after anticoagulation did not differ significantly between the two groups. Two patients died after warfarin therapy, but the causes of death were not related to anticoagulation. Conclusions: Warfarin can be safely administered to cirrhotic patients with nonmalignant PVT. The presence of preexisting portal hypertension is a predictor of nonresponse to anticoagulation.
Abstract
Background/Aims: Portal-vein thrombosis (PVT) develops in 10–25% of cirrhotic patients and may aggravate portal hypertension. There are few data regarding the effects of anticoagulation on nonmalignant PVT in liver cirrhosis. The aim of this study was to elucidate the safety, efficacy, and predictors of response to anticoagulation therapy in cirrhotic patients. Methods: Patients with liver cirrhosis and nonmalignant PVT were identified by a hospital electronic medical record system (called BESTCARE). Patients with malignant PVT, Budd-Chiari syndrome, underlying primary hematologic disorders, or preexisting extrahepatic thrombosis were excluded from the analysis. Patients were divided into two groups (treatment and nontreatment), and propensity score matching analysis was performed to identify control patients. The sizes of the thrombus and spleen were evaluated using multidetector computed tomography . Results: Twenty-eight patients were enrolled in this study between 2003 and 2014: 14 patients who received warfarin for nonmalignant PVT and 14 patients who received no anticoagulation. After 112 days of treatment, 11 patients exhibited significantly higher response rates (complete in 6 and partial in 5) compared to the control patients, with decreases in thrombus size of >30%. Compared to nonresponders, the 11 responders were older, and had a thinner spleen and fewer episodes of previous endoscopic variceal ligations, whereas pretreatment liver function and changes in prothrombin time after anticoagulation did not differ significantly between the two groups. Two patients died after warfarin therapy, but the causes of death were not related to anticoagulation. Conclusions: Warfarin can be safely administered to cirrhotic patients with nonmalignant PVT. The presence of preexisting portal hypertension is a predictor of nonresponse to anticoagulation.
참고문헌 (21)
- Boyer TD, "Portal vein thrombosis in patients with cirrhosis", Clinical Liver Disease, 3, pp.111~113 (2014)
- Aqel BA., "Practical Gastroenterology and Hepatology: Liver and Biliary Disease", pp.261~274 (2010), Wiley-Blackwell
- Garcia-Pagan JC, "Extrahepatic portal vein thrombosis", Semin Liver Dis, 28, pp.282~292 (2008)
- DeLeve LD, "Vascular disorders of the liver", Hepatology, 49, pp.1729~1764 (2009)
- Englesbe MJ, "Portal vein thrombosis and liver transplant survival benefit", Liver Transpl, 16, pp.999~1005 (2010)
- Amitrano L, "Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis", J Clin Gastroenterol, 44, pp.448~451 (2010)
- Delgado MG, "Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis", Clin Gastroenterol Hepatol, 10, pp.776~783 (2012)
- Villa E, "Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis", Gastroenterology, 143, pp.1253~1260 (2012)
- Werner KT, "Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation", Dig Dis Sci, 58, pp.1776~1780 (2013)
- D’Agostino RB, Jr., "Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group", Stat Med, 17, pp.2265~2281 (1998)
- Rubin DB., "Estimating causal effects from large data sets using propensity scores", Ann Intern Med, 127, pp.757~763 (1997)
- Hosaka T, "Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection", Hepatology, 58, pp.98~107 (2013)
- Lim YS, "Mortality, Liver Transplantation, and Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B Treated With Entecavir vs Lamivudine", Gastroenterology, 147, pp.152~161 (2014)
- Senzolo M, "Anticoagulation for portal vein thrombosis in cirrhotic patients should be always considered", Intern Emerg Med, 4, pp.161~162 (2009)
- Tripodi A, "Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests", Hepatology, 41, pp.553~558 (2005)
- Søgaard KK, "Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study", Am J Gastroenterol, 104, pp.96~101 (2009)
- Arjal R, "International normalized ratio of prothrombin time in the model for end-stage liver disease score: an unreliable measure", Clin Liver Dis, 13, pp.67~71 (2009)
- Tripodi A., "Tests of coagulation in liver disease", Clin Liver Dis, 13, pp.55~61 (2009)
- Ben-Ari Z, "Disseminated intravascular coagulation in liver cirrhosis: fact or fiction?", Am J Gastroenterol, 94, pp.2977~2982 (1999)
- García-Pagán JC, "Early use of TIPS in patients with cirrhosis and variceal bleeding", N Engl J Med, 362, pp.2370~2379 (2010)
- Luca A, "Natural course of extrahepatic nonmalignant Partial Portal Vein Thrombosis in Patients with cirrhosis", Radiology, 265, pp.124~132 (2012)